Neurotransmitters are endogenous chemical messengers which play an important role in many of the brain functions, abnormal levels being correlated with physical, psychotic and neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease. Therefore, their sensitive and robust detection is of great clinical significance. Electrochemical methods have been intensively used in the last decades for neurotransmitter detection, outclassing more complicated analytical techniques such as conventional spectrophotometry, chromatography, fluorescence, flow injection, and capillary electrophoresis. In this manuscript, the most successful and promising electrochemical enzyme-free and enzymatic sensors for neurotransmitter detection are reviewed. Focusing on the activity of worldwide researchers mainly during the last ten years (2010–2019), without pretending to be exhaustive, we present an overview of the progress made in sensing strategies during this time. Particular emphasis is placed on nanostructured-based sensors, which show a substantial improvement of the analytical performances. This review also examines the progress made in biosensors for neurotransmitter measurements in vitro, in vivo and ex vivo.

During the last few decades, magnetic nanoparticles have been evaluated as promising materials in the field of cancer detection, screening, and treatment. Early diagnosis and screening of cancer may be achieved using magnetic nanoparticles either within the magnetic resonance imaging technique and/or sensing systems. These sensors are designed to selectively detect specific biomarkers, compounds that can be related to the onset or evolution of cancer, during and after the treatment of this widespread disease. Some of the particular properties of magnetic nanoparticles are extensively exploited in cancer therapy as drug delivery agents to selectively target the envisaged location by tailored in vivo manipulation using an external magnetic field. Furthermore, individualized treatment with antineoplastic drugs may be combined with magnetic resonance imaging to achieve an efficient therapy. This review summarizes the studies about the implications of magnetic nanoparticles in cancer diagnosis, treatment and drug delivery as well as prospects for future development and challenges of magnetic nanoparticles in the field of oncology.

In this work, we propose an electrochemical DNA aptasensor for the detection of profenofos, an organophosphorus pesticide, based on a competitive format and disposable graphite screen-printed electrodes (GSPEs). A thiol-tethered DNA capture probe, which results to be complementary to the chosen aptamer sequence, was immobilised on gold nanoparticles/polyaniline composite film-modified electrodes (AuNPs/PANI/GSPE). Different profenofos solutions containing a fixed amount of the biotinylated DNA aptamer were dropped onto the realized aptasensors. The hybridisation reaction was measured using a streptavidin-alkaline phosphatase enzyme conjugate, which catalyses the hydrolysis of 1-naphthyl -phosphate. The 1-naphtol enzymatic product was detected by means of differential pulse voltammetry (DPV). The aptasensor showed itself to work as a signal off sensor, according to the competitive format used. A dose response curve was obtained between 0.10 μM and 10 μM with a detection limit of 0.27 μM.